TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency

Natalizumab blocks α4‐integrin‐mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompted by diminished CNS immune surveillance. The initial host response to viral infections entails the synthesis of type I interferons (IFN) upon engagement of TLR3 receptors. We hypothesized that TLR3 agonism reestablishes CNS immune competence in the setting of α4‐integrin deficiency.

[1]  G. Cutter,et al.  Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[2]  S. Richman,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies , 2017, The Lancet Neurology.

[3]  G. Learn,et al.  Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness , 2017, Proceedings of the National Academy of Sciences.

[4]  A. Harandi,et al.  Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection , 2016, npj Vaccines.

[5]  R. Fox,et al.  Erratum to: Reassessing the risk of natalizumab-associated PML , 2016, Journal of NeuroVirology.

[6]  Shwetank,et al.  Type I Interferons Regulate the Magnitude and Functionality of Mouse Polyomavirus-Specific CD8 T Cells in a Virus Strain-Dependent Manner , 2016, Journal of Virology.

[7]  R. Fox,et al.  Reassessing the risk of natalizumab-associated PML , 2016, Journal of NeuroVirology.

[8]  T. Pietschmann,et al.  Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication , 2016, Antimicrobial Agents and Chemotherapy.

[9]  L. Hayardeny,et al.  Immune surveillance of the central nervous system in multiple sclerosis — Relevance for therapy and experimental models , 2014, Journal of Neuroimmunology.

[10]  G. Cutter,et al.  Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? , 2014, Multiple sclerosis.

[11]  Linda J. Scarazzini,et al.  Progressive multifocal leukoencephalopathy after natalizumab discontinuation , 2014, Annals of neurology.

[12]  H. Hartung,et al.  The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis , 2013, Journal of Neuroinflammation.

[13]  R. Gold,et al.  Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  C. Mallard.  Innate Immune Regulation by Toll-Like Receptors in the Brain , 2012, ISRN neurology.

[15]  E. Bettelli,et al.  Cutting Edge: Loss of α4 Integrin Expression Differentially Affects the Homing of Th1 and Th17 Cells , 2011, The Journal of Immunology.

[16]  B. Hemmer,et al.  Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE , 2011, The Journal of experimental medicine.

[17]  David W. Holman,et al.  The blood-brain barrier, chemokines and multiple sclerosis. , 2011, Biochimica et biophysica acta.

[18]  G. Krishnamoorthy,et al.  Functional and Pathogenic Differences of Th1 and Th17 Cells in Experimental Autoimmune Encephalomyelitis , 2010, PloS one.

[19]  C. Cunningham,et al.  Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNα/β and IL-1β responses in the diseased brain and exacerbates chronic neurodegeneration , 2010, Brain, Behavior, and Immunity.

[20]  D. Clifford,et al.  Natalizumab-associated progressive multifocal leukoencephalopathy. , 2012 .

[21]  B. Engelhardt,et al.  β1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity , 2009, Proceedings of the National Academy of Sciences.

[22]  D. Miller,et al.  Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.

[23]  B. Hemmer,et al.  Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. , 2008, Archives of neurology.

[24]  S. Croul,et al.  Detection of JC virus DNA fragments but not proteins in normal brain tissue , 2008, Annals of neurology.

[25]  H. Hartung,et al.  The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. , 2008, Blood.

[26]  Kai-Hsin Chang,et al.  Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. , 2008, Blood.

[27]  Laarni Sumibcay,et al.  Interferon-α and -β Restrict Polyomavirus JC Replication in Primary Human Fetal Glial Cells: Implications for Progressive Multifocal Leukoencephalopathy Therapy , 2007 .

[28]  A. Bar-Or,et al.  Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis , 2006 .

[29]  K. Honda,et al.  Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors , 2006 .

[30]  S. Cepok,et al.  Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.

[31]  J. Berger,et al.  Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab , 2006, Neurological research.

[32]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[33]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[34]  R. Alon,et al.  Immune cell migration in inflammation: present and future therapeutic targets , 2005, Nature Immunology.

[35]  S. Croul,et al.  Re: Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories by Rollison et al. (published online 21 October 2004) , 2005, International journal of cancer.

[36]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[37]  B. Becher,et al.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis , 2005, Nature Medicine.

[38]  Jean Hou,et al.  Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories , 2005, International journal of cancer.

[39]  R. Flavell,et al.  Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Scott,et al.  Deletion of α4 Integrins from Adult Hematopoietic Cells Reveals Roles in Homeostasis, Regeneration, and Homing , 2003, Molecular and Cellular Biology.

[41]  R. Ransohoff,et al.  Three or more routes for leukocyte migration into the central nervous system , 2003, Nature Reviews Immunology.

[42]  P. Hertzog,et al.  Characterization and transcriptional analysis of the mouse Chromosome 16 cytokine receptor gene cluster , 2003, Mammalian Genome.

[43]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[44]  J. Soto-Hernández,et al.  [The neurologic diseases]. , 2002, Gaceta medica de Mexico.

[45]  J. Schmitz,et al.  Association of Prolonged Survival in HLA-A2+ Progressive Multifocal Leukoencephalopathy Patients with a CTL Response Specific for a Commonly Recognized JC Virus Epitope1 , 2002, The Journal of Immunology.

[46]  V. Kuchroo,et al.  Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. , 2001, The Journal of clinical investigation.

[47]  A. Adamis,et al.  Sensitive blood-retinal barrier breakdown quantitation using Evans blue. , 2001, Investigative ophthalmology & visual science.

[48]  M. Racke.  Experimental Autoimmune Encephalomyelitis (EAE) , 2001, Current protocols in neuroscience.

[49]  M. Lichterfeld,et al.  Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4 , 2000, British journal of haematology.

[50]  E. Kunkel,et al.  Leukocyte Arrest During Cytokine-Dependent Inflammation In Vivo1 , 2000, The Journal of Immunology.

[51]  R. Pardi,et al.  Regulation of lymphocyte traffic by adhesion molecules , 1999, Inflammation Research.

[52]  E. Bouza,et al.  Treatment of AIDS‐associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy , 1998, AIDS.

[53]  D. Levy,et al.  Differential viral induction of distinct interferon‐α genes by positive feedback through interferon regulatory factor‐7 , 1998, The EMBO journal.

[54]  O. Stuve,et al.  Interferon beta in the treatment of multiple sclerosis , 1998, Neurology.

[55]  M. Yamaguchi,et al.  Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G0/G1 versus S+G2/M phases of the cell cycle. , 1998, Blood.

[56]  G. Tjønnfjord,et al.  Efflux of CD34+ cells from bone marrow to peripheral blood is selective in steady-state hematopoiesis and during G-CSF administration. , 1997, Journal of hematotherapy.

[57]  H. Thomas,et al.  Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[58]  J. Uhm,et al.  Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9 , 1996 .

[59]  E. Major,et al.  JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency , 1996, Journal of virology.

[60]  S. Miller,et al.  Experimental Autoimmune Encephalomyelitis in the Mouse , 1996, Current protocols in immunology.

[61]  P. Cinque,et al.  JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[62]  M Aguet,et al.  Inducible gene targeting in mice , 1995, Science.

[63]  K. Sundqvist,et al.  Functional specialization of fibronectin-binding beta 1-integrins in T lymphocyte migration. , 1994, Journal of immunology.

[64]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.

[65]  C. Bever,et al.  Gamma‐interferon induction in patients with chronic progressive MS , 1991, Neurology.

[66]  H. Lassmann,et al.  Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system. , 1990, The American journal of pathology.

[67]  C. Bever,et al.  The kinetics of interferon induction by poly ICLC in humans. , 1988, Journal of interferon research.

[68]  W. Hickey,et al.  Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. , 1988, Science.

[69]  C. Bever,et al.  Preliminary trial of poly ICLC in chronic progressive multiple sclerosis , 1986, Neurology.

[70]  C. Bever,et al.  A preliminary trial of poly(I,C)-LC in multiple sclerosis. , 1985, Journal of biological response modifiers.

[71]  M. Aguet.  High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor , 1980, Nature.

[72]  K. Cantell,et al.  Interferon Crosses Blood-Cerebrospinal Fluid Barrier in Monkeys 1 , 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[73]  S. Baron,et al.  Interferon in rabbit brain, cerebrospinal fluid and serum following administration of polyinosinic-polycytidylic acid. , 1970, Journal of immunology.

[74]  L. Law,et al.  Inhibition of tumor growth by polyinosinic-polycytidylic acid. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Ibla,et al.  Methods to assess tissue permeability. , 2013, Methods in molecular biology.

[76]  A. Antinori,et al.  Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA) , 2011, Journal of NeuroVirology.

[77]  Laarni Sumibcay,et al.  Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy. , 2007, The Journal of infectious diseases.

[78]  K. Honda,et al.  Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. , 2006, Immunity.

[79]  T. Papayannopoulou,et al.  Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. , 2000, Seminars in hematology.

[80]  G Leone,et al.  Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF , 1999, Bone Marrow Transplantation.

[81]  G. D. Dal Pan,et al.  Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. , 1998, Journal of neurovirology.

[82]  J. Uhm,et al.  Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. , 1996, Annals of neurology.

[83]  F. Mandelli,et al.  Alpha-interferon therapy in a case of probable progressive multifocal leukoencephalopathy. , 1992, Acta neurologica Belgica.

[84]  E. De Clercq.  Degradation of poly(inosinic acid) - poly(cytidylic acid) [(I)n - (C)n] by human plasma. , 1979, European Journal of Biochemistry.

[85]  E. Clercq.  Degradation of Poly(inosinic acid) · poly(cytidylic acid) [(I)n· (Cn)] by Human Plasma , 1979 .